Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Acquisitions & Divestments (2022 - 2025)

Harmony Biosciences Holdings' Change in Acquisitions & Divestments history spans 4 years, with the latest figure at $20.6 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 31.49% year-over-year to $20.6 million; the TTM value through Dec 2025 reached $81.1 million, down 17.73%, while the annual FY2025 figure was $81.1 million, 17.73% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $20.6 million at Harmony Biosciences Holdings, up from $19.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $46.0 million in Q1 2023 and bottomed at $8.2 million in Q4 2022.
  • The 4-year median for Change in Acquisitions & Divestments is $21.6 million (2025), against an average of $23.5 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 175.98% in 2023 before it plummeted 58.85% in 2024.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $8.2 million in 2022, then skyrocketed by 175.98% to $22.6 million in 2023, then skyrocketed by 32.66% to $30.0 million in 2024, then plummeted by 31.49% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Change in Acquisitions & Divestments are $20.6 million (Q4 2025), $19.6 million (Q3 2025), and $19.3 million (Q2 2025).